Clinical trials: Ticagrelor
Chronic Kidney Disease
Ticagrelor and Anti-inflammatory Effects
Antiplatelet treatment in patients with end stage renal disease (ESRD) on hemodialysis (HD) is still challenging because of bleeding and thrombotic complications.
- Trial name
- NCT02406911
- Testing
- Ticagrelor
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Kyunghee University Medical Center
Hemorrhage, Surgical, Blood Loss, Surgical
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent…
- Conditions
- Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
- Trial name
- STAR-T (NCT04976530)
- Testing
- DrugSorb-ATR system
- Where
- 29 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- CytoSorbents, Inc
Acute Coronary Syndrome
Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not?
After a heart attack patients are routinely started on drugs to inhibit platelets. Ticagrelor is a powerful anti-platelet drug with clinical benefits.
- Trial name
- NCT02054663
- Testing
- Clopidogrel
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Acute Myocardial Infarction
Ticagrelor for PCI Post Thrombolysis
Ticagrelor is a first line therapy along with aspirin for patients undergoing primary PCI for STEMI. However, many patients are still treated with fibrinolytic therapy and the safety and efficacy of Ticagrelor has not been…
- Trial name
- SETFAST (NCT01930591)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 5 sites in Canada
- Volunteers
- 140 people
- Sponsor
- Unity Health Toronto
Ischemia
The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment
To investigate if treatment with ticagrelor can mitigate the transient loss of endothelium-dependent vasodilatation of the resistance vasculature following a short period of ischemia, compared with clopidogrel at standard…
- Trial name
- NCT02580149
- Testing
- Ticagrelor, Clopidogrel
- Where
- Austria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Michael Wolzt, Prof. MD
Myocardial Infarction, Thrombosis
CES1 Crossover Trial of Clopidogrel and Ticagrelor
The purpose of this investigation is to evaluate when genetic variation in the carboxylesterase 1 (CES1) gene influences antiplatelet therapy response, as assessed by ex vivo platelet aggregometry, in healthy participants treated…
- Conditions
- Myocardial Infarction, Thrombosis, Platelet Dysfunction
- Trial name
- NCT03161678
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Myocardial Ischemia
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease
The aim of this study is to assess the pleiotropic effects of ticagrelor that could represent possible mechanisms for its beneficial effects on cardiovascular mortality. We will test three different hypotheses: 1.
- Trial name
- TAPER-S (NCT02701140)
- Testing
- Coronary stenting, intracoronary ECG recording, Coronary Flow reserve
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Italo Porto
Coronary Artery Disease
Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Assess the pharmacodynamic effect of ticagrelor vs. Clopidogrel in American Indian patients with stable coronary artery disease.
- Trial name
- NCT01706510
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rapid City Regional Hospital, Inc
Myocardial Infarction
Ticagrelor Pharmacokinetics in NSTEMI
Patients with myocardial infarction, which does not include all layers of the heart's muscle wall are common and they often receive pharmacological treatment with the platelet inhibiting drug ticagrelor.
- Trial name
- NCT02292277
- Testing
- Ticagrelor
- Where
- Sweden
- Volunteers
- 63 people
- Sponsor
- Karolinska University Hospital
Platelet Reactivity
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
Clopidogrel administration is commonly prescribed in patients undergoing percutaneous coronary intervention, in patients with previous stroke and in patients under chronic hemodialysis via fistulae.
- Trial name
- NCT01511471
- Testing
- Ticagrelor
- Where
- 2 sites in Greece
- Volunteers
- 20 people
- Sponsor
- University of Patras
Healthy
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female…
- Trial name
- NCT03430661
- Testing
- ACT-246475, Clopidogrel, Prasugrel
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Acute Coronary Syndrome, STEMI
Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study
To examine the efficacy of chewing Ticagrelor versus Prasugrel in ST-elevation Myocardial Infarction (STEMI) patients on platelet reactivity.
- Trial name
- NCT03016611
- Testing
- Chewing Ticagrelor LD, Chewing Prasugrel LD
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Acute Myocardial Infarction, Cardiogenic Shock
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
Multicenter, international, randomized, placebo-controlled, double-blind trial comparing intravenous cangrelor and crushed oral ticagrelor in patients with acute myocardial infarction complicated by initial cardiogenic shock…
- Trial name
- DAPT-SHOCK-AMI (NCT03551964)
- Testing
- Cangrelor, Ticagrelor
- Where
- 29 sites in Czechia, France and 3 more
- Volunteers
- 605 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Outcomes in UK ACS Patients Prescribed Ticagrelor
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015…
- Trial name
- NCT03058601
- Where
- United Kingdom
- Volunteers
- 1,650 people
- Sponsor
- AstraZeneca
Coronary Artery Bypass, Antiplatelet Agents
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1…
- Trial name
- DACAB (NCT02201771)
- Testing
- Aspirin, Ticagrelor
- Where
- 6 sites in China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Acute Coronary Syndrome Patients With Diabetes After PCI
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
In this study, the investigates try to confirm the hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in acute coronary syndrome patients with diabetes.
- Trial name
- TIGER-diabetes (NCT04307511)
- Testing
- Ticagrelor, Aspirin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Tong Ren Hospital
Acute Coronary Syndrome, Coronary Artery Disease
Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study
Subjects with acute coronary syndromes scheduled for cardiac catheterization will be enrolled in this study. Subjects that are to be treated clinically with coronary artery stenting will be randomized to receive a loading dose of…
- Trial name
- NCT01826175
- Testing
- Ticagrelor, Clopidogrel, Optical Coherence Tomography
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Acute Coronary Syndome
Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?
Background Acute coronary syndrome (ACS) is a term representing all diseases related to reduction in blood flow to the heart characterised by clot formation over a segment of blood vessel narrowing.
- Trial name
- PLATE NOX (NCT02169596)
- Testing
- Ticagrelor, EndoPAT - endothelial assessment
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications.
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular Procedure
- Trial name
- TALISCHER-SAH (NCT07821008)
- Testing
- Experimental group: ticagrelor
- Where
- 7 sites in France
- Volunteers
- 274 people
- Sponsor
- University Hospital, Toulouse